Hims, The Surprise Winner Of The FDA Showdown With Peptides, Bounds Higher
Hims, The Surprise Winner Of The FDA Showdown With Peptides, Bounds Higher
Unusual Whales
The stock of Hims surged on Thursday following an FDA panel's suggestion to compound a well-liked peptide for injury recovery. This recommendation led to a significant increase in Hims' stock price. This development made Hims a surprise winner in the FDA showdown regarding peptides.
